Phaseline

Companies › Tesaro

Tesaro: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Niraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Ovarian NeoplasmsApr 2029
Cobolimab (TSR-022)
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 1NeoplasmsMar 2027
TSR-033–Phase 1NeoplasmsMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02655016NiraparibPhase 3Ovarian NeoplasmsOncologyMay 2019
NCT02817633Cobolimab (TSR-022)Phase 1NeoplasmsOncologyMar 2027
NCT02817633TSR-033Phase 1NeoplasmsOncologyMar 2027
NCT03602859NiraparibPhase 3Ovarian NeoplasmsOncologyApr 2029

Targets

PARP2 (1) PARP1 (1) HAVCR2 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) GSK Pfizer Johnson & Johnson (Janssen) BeiGene Impact Therapeutics pharmaand Allarity Therapeutics Boryung Pharmaceutical

Companies built like this

pharmaand Immatics US Vividion Therapeutics Vyriad Takara Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.